Abstract: The present disclosure relates to antibodies and antibody conjugates that selectively bind to tissue factor and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies and antibody conjugates, such as therapeutic and diagnostic methods.

Abstract: A connection pairing method is used to establish a wireless transmission connection between a first electronic device and a second electronic device. Each electronic device is capable of operating in a wireless network mode and/or a network hotspot mode. The connection pairing method includes disabling the network hotspot mode of the first electronic device, connecting the first electronic device to the hotspot of the second electronic device, and transmitting the hotspot connection information of the first electronic device to the second electronic device; upon receiving the hotspot connection information of the first electronic device, setting the second electronic device to wireless network mode and enabling the network hotspot mode of the first electronic device; and establishing a hotspot connection between the second electronic device and the first electronic device based on the hotspot connection information.

Abstract: A MINI LED driving power supply and a MINI LED television, the MINI LED driving power supply includes a power supply board connecting with a mainboard and a MINI LED screen, the power supply board includes a first conversion module and a second conversion module; the first conversion module outputs power supply voltage to power the mainboard after the first conversion module is turned on, outputs first voltage and second voltage to power the mainboard according to a power-on/off signal output by the mainboard, and outputs first power supply and high-voltage direct current to the second conversion module; the second conversion module converts high-voltage direct current into third voltage and outputs the third voltage to the MINI LED screen according to enable signal output by the mainboard and the first power supply, to light up MINI LED screen.

Abstract: The present disclosure provides methods and compositions useful for diagnosing and treating activated alternative pathway of complement in a human subject with a SARS-CoV-2 infection. Also provided are methods of treating an infection by a betacoronavirus, e.g., SARS-CoV, MERS-CoV, or SARS-CoV-2, in a human subject. The methods of treatment include administering to the human subject a therapeutically effective amount of at least one complement factor D inhibitor. Also provided herein are compounds for treating an infection by a betacoronavirus and their use in the manufacture in a medicament for treating an infection by a betacoronavirus.

Abstract: A MINI LED driving power supply and a MINI LED television, the MINI LED driving power supply includes a power supply board connecting with a mainboard and a MINI LED screen, the power supply board includes a first conversion module and a second conversion module; the first conversion module outputs power supply voltage to power the mainboard after the first conversion module is turned on, outputs first voltage and second voltage to power the mainboard according to a power-on/off signal output by the mainboard, and outputs first power supply and high-voltage direct current to the second conversion module; the second conversion module converts high-voltage direct current into third voltage and outputs the third voltage to the MINI LED screen according to enable signal output by the mainboard and the first power supply, to light up MINI LED screen.

Abstract: The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for identifying patients having a complement-mediated disease that could benefit from treatment with complement inhibitors. As described herein, the present invention utilizes patient sera and flow cytometry in the companion diagnostic assay. More specifically, the present invention comprises evaluating complement activity via cell surface deposition of C5b-9 and, in further embodiments, complement-dependent cell killing (the modified Ham assay) using patient sera.